# Mineralys Therapeutics, Inc. (MLYS): MoatMap facts

As of 14 Nov 2026. Research data, not investment advice.

As of 14 Nov 2026, the MoatMap Score for Mineralys Therapeutics, Inc. (MLYS) is 6/100, ranked against 25,000+ stocks in 38 markets (Quality 29, Value 28, Momentum 18, each scored against its sector).

- MoatMap Score: 6/100, a percentile across 25,000+ stocks in 38 markets (100 is best).
- Quality 29, Value 28, Momentum 18: each a 0-100 percentile within Healthcare.
- Position: #24,993 overall, #2,446 in Healthcare.
- Listing: United States, NMS; Healthcare / Biotechnology.
- Last close: 15.33 USD on 13 Nov 2026.
- Insider filings, last 180 days: directors sold USD 11.9M.

Source: https://moatmap.ai/stock/MLYS
How the scores work: https://moatmap.ai/methodology
Does the score work? Each tenth of the ranking is tracked monthly: https://moatmap.ai/decile-tracker
